YAP1 Is a Crucial Nexus in the Tumor Microenvironment

Abstract

Yes-associated protein-1 (YAP1) is an oncogenic effector of the Hippo signaling pathway, activated in several cancer types, and has been extensively studied in cancer progression and therapy. A large number of studies have established the importance of YAP1 in promoting cell-autonomous functions, including uncontrolled growth, sustained proliferative signaling, drug resistance, and metastasis, across multiple cancer types. Therapeutic targeting of YAP1 to combat incurable neoplasms has been the focus of intense investigations. Solid tumors exhibit an organ-like morphology that comprises malignant cells, nonmalignant cells such as fibroblasts, endothelial cells, and immune cells, and non-cellular components, including the extracellular matrix and exosomal vesicles. Tumor progression is accompanied by persistent, reciprocal interactions between malignant cells and other cell types in the tumor microenvironment (TME). Ample evidence indicates the functional importance of YAP1 in nonmalignant components of the TME, which fuel cancer progression. In this review, we provide a comprehensive overview of the functional significance of YAP1 and its downstream signaling pathways across different compartments of the TME, which orchestrate cancer growth, stemness, drug resistance, and metastasis. In particular, this review focuses on understanding the mechanisms by which YAP1 drives distinct cell types in the TME, including cancer-associated fibroblasts (CAFs), immune cells, endothelial cells, and exosome-derived factors, to fuel tumor progression. Furthermore, we summarize the progress in the development of recent YAP1 inhibitors, their mechanisms of action in Hippo-YAP1-dependent cancers, and their combination benefits with existing treatment strategies.

Keywords

Yes-associated protein 1 / Tumor stroma / Tumor microenvironment / Cancer-associated fibroblasts / Cancer stem cells / Tumor-associated macrophages / Hippo signaling pathway / TEAD / Tumor angiogenesis / Exosomes

References

[1] Abraham O, Szela L, Feng Eet al. . Exploring youth perceptions about cancer prevention and preferences for education: a qualitative study. J Cancer Educ.. 2023, 38(1): 50-59.

[2] Bray F, Laversanne M, Sung Het al. . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin.. 2024, 74(3): 229-263

[3] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer J Clin.. 2024, 74(1): 12-49

[4] Shaji A, Keechilat P, Dk Vet al. . Analysis of the mortality trends of 23 major cancers in the Indian population between 2000 and 2019: a joinpoint regression analysis. JCO Glob Oncol.. 2023, 9. e2200405

[5] Abbas Z, Rehman S. An Overview of Cancer Treatment Modalities. Neoplasm. 2018. https://api.semanticscholar.org/CorpusID:81915945.

[6] Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Technol.. 2024, 5: 109-122.

[7] Mirzayans R, Murray D. What are the reasons for continuing failures in cancer therapy are misleading/inappropriate preclinical assays to be blamed, might some modern therapies cause more harm than benefit. Int J Mol Sci.. 2022, 23(21): 13217.

[8] Baghban R, Roshangar L, Jahanban-Esfahlan Ret al. . Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal.. 2020, 18159.

[9] Salvatore V, Teti G, Focaroli Set al. . The tumor microenvironment promotes cancer progression and cell migration. Oncotarget.. 2017, 869608-9616.

[10] Bora-Singhal N, Saha B, Mohankumar Det al. . A novel PHD2/VHL-mediated regulation of YAP1 contributes to VEGF expression and angiogenesis. Cancer Res Commun.. 2022, 2(7): 624-638.

[11] Nallasamy P, Nimmakayala RK, Parte Set al. . Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis. Mol Cancer.. 2022, 21(1): 225.

[12] Salemme V, Centonze G, Avalle Let al. . The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. Front Oncol.. 2023, 13: 1170264.

[13] Shen T, Li Y, Zhu Set al. . YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression. J Exp Clin Cancer Res.. 2020, 39136.

[14] Ishii G, Ochiai A, Neri S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev.. 2016, 99186-196.

[15] Wong KY, Cheung AH, Chen Bet al. . Cancer-associated fibroblasts in nonsmall cell lung cancer: From molecular mechanisms to clinical implications. Int J Cancer.. 2022, 15181195-1215.

[16] Sun S, Zhang Y, Li Yet al. . Crosstalk between colorectal cancer cells and cancer-associated fibroblasts in the tumor microenvironment mediated by exosomal noncoding RNAs. Front Immunol.. 2023, 14: 1161628.

[17] Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans.. 2017, 45(1): 229-236.

[18] Chen WJ, Ho CC, Chang YLet al. . Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun.. 2014, 5: 3472.

[19] Yoshida T, Ishii G, Goto Ket al. . Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res.. 2015, 213642-651.

[20] Shintani Y, Fujiwara A, Kimura Tet al. . IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J Thorac Oncol.. 2016, 1191482-1492.

[21] Sun M, Wang X, Shou Yet al. . Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma. Sci Rep.. 2023, 13(1): 9671.

[22] Mammoto T, Jiang A, Jiang Eet al. . Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. Am J Pathol.. 2013, 18341293-1305.

[23] Henke E, Nandigama R, Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci.. 2019, 6: 160.

[24] Schober M, Jesenofsky R, Faissner Ret al. . Desmoplasia and chemoresistance in pancreatic cancer. Cancers.. 2014, 6(4): 2137-2154.

[25] Stacy RC, Jakobiec FA, Fay A. Collagenous fibroma (desmoplastic fibroblastoma) of the orbital rim. Ophthalmic Plast Reconstr Surg.. 2013, 294e101-e104.

[26] Pandol S, Edderkaoui M, Gukovsky Iet al. . Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol.. 2009, 7(11): S44-S47.

[27] Sato H, Hara T, Meng Set al. . Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: Current understanding and future directions. Cancer Sci.. 2023, 114(9): 3487-3495.

[28] Parker AL, Cox TR. The role of the ECM in lung cancer dormancy and outgrowth. Front Oncol.. 2020, 10: 1766.

[29] Laczko R, Csiszar K. Lysyl oxidase (LOX): functional contributions to signaling pathways. Biomolecules.. 2020, 10(8): 1093.

[30] Sandha KK, Shukla MK, Gupta PN. Recent advances in strategies for extracellular matrix degradation and synthesis inhibition for improved therapy of solid tumors. Curr Pharm Des.. 2020, 26425456-5467.

[31] Ferreira S, Saraiva N, Rijo Pet al. . LOXL2 inhibitors and breast cancer progression. Antioxidants (Basel).. 2021, 102312.

[32] Buhren BA, Schrumpf H, Hoff NPet al. . Hyaluronidase: from clinical applications to molecular and cellular mechanisms. Eur J Med Res.. 2016, 21: 5.

[33] Goliwas KF, Deshane JS, Elmets CAet al. . Moving immune therapy forward targeting TME. Physiol Rev.. 2021, 1012417-425.

[34] Gerwins P, Sköldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol.. 2000, 343185-194.

[35] Arora L, Kalia M, Dasgupta Set al. . Development of a multicellular 3D tumor model to study cellular heterogeneity and plasticity in NSCLC tumor microenvironment. Front Oncol.. 2022, 12. 881207

[36] Kim I, Choi S, Yoo Set al. . Cancer-associated fibroblasts in the hypoxic tumor microenvironment. Cancers.. 2022, 14(14): 3321.

[37] Ioannidou E, Moschetta M, Shah Set al. . Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets. Int J Mol Sci.. 2021, 22189926.

[38] Renner K, Singer K, Koehl GEet al. . Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol.. 2017, 8: 248.

[39] Lei X, Lei Y, Li JKet al. . Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett.. 2020, 470126-133.

[40] Wang J, Li D, Cang Het al. . Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med.. 2019, 8104709-4721.

[41] Yuan JQ, Zhang KJ, Wang SMet al. . YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer. Gland Surg.. 2021, 10(9): 2799-2814.

[42] Croci DO, Zacarías Fluck MF, Rico MJet al. . Dynamic crosstalk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother.. 2007, 56(11): 1687-1700.

[43] Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res.. 2006, 66(2): 605-612.

[44] Friedmann KS, Kaschek L, Knörck Aet al. . Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells. J Physiol.. 2022, 600(23): 5027-5054.

[45] Shibata M, Ham K, Hoque MO. A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J Cancer.. 2018, 143(9): 2133-2144.

[46] Tang W, Li M, Yangzhong Xet al. . Hippo signaling pathway and respiratory diseases. Cell Death Discov.. 2022, 8(1): 213.

[47] Li Z, Zhao B, Wang Pet al. . Structural insights into the YAP and TEAD complex. Genes Dev.. 2010, 243235-240.

[48] Bora-Singhal N, Nguyen J, Schaal Cet al. . YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem Cells.. 2015, 33(6): 1705-1718.

[49] Luo J, Deng L, Zou Het al. . New insights into the ambivalent role of YAP/TAZ in human cancers. J Exp Clin Cancer Res.. 2023, 42(1): 130.

[50] Szulzewsky F, Holland EC, Vasioukhin V. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Dev Biol.. 2021, 475: 205-221.

[51] Pearson JD, Huang K, Pacal Met al. . Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anticancer YAP/TEAD activity. Cancer Cell.. 2021, 3981115-1134.e12.

[52] Tu B, Yao J, Ferri-Borgogno Set al. . YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight.. 2019, 4(21. e130811

[53] Edwards AC, Stalnecker CA, Jean Morales Aet al. . TEAD inhibition overcomes YAP1/TAZ-driven primary and acquired resistance to KRASG12C inhibitors. Cancer Res.. 2023, 8324): 4112-4129.

[54] Miyanaga A, Masuda M, Tsuta Ket al. . Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing. J Thorac Oncol.. 2015, 10(5): 844-851.

[55] Sanchez-Vega F, Mina M, Armenia Jet al. . Oncogenic signaling pathways in the cancer genome atlas. Cell.. 2018, 173(2): 321-337.e10.

[56] Wang Y, Xu X, Maglic Det al. . Comprehensive molecular characterization of the hippo signaling pathway in cancer. Cell Rep.. 2018, 25(5): 1304-1317.e5.

[57] Calvet L, Dos-Santos O, Spanakis Eet al. . YAP1 is essential for malignant mesothelioma tumor maintenance. BMC Cancer.. 2022, 22(1): 639.

[58] Guerrant W, Kota S, Troutman Set al. . YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2-EGFR signaling axis. Cancer Res.. 2016, 76123507-3519.

[59] Kandasamy S, Adhikary G, Rorke EAet al. . The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype. Mol Cancer Res.. 2020, 18(3): 343-351.

[60] Kaneda A, Seike T, Danjo Tet al. . The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an antitumor effect on malignant pleural mesothelioma. Am J Cancer Res.. 2020, 10(12): 4399-4415

[61] Tang TT, Konradi AW, Feng Yet al. . Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. Mol Cancer Ther.. 2021, 20(6): 986-998.

[62] Sun Y, Hu L, Tao Zet al. . Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells. Nat Commun.. 2022, 13(1): 6744.

[63] Chapeau EA, Sansregret L, Galli GGet al. . Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer.. 2024, 571102-1120.

[64] Shao DD, Xue W, Krall EBet al. . KRAS and YAP1 converge to regulate EMT and tumor survival. Cell.. 2014, 158(1): 171-184.

[65] Stoner SA, Yan M, Liu KTHet al. . Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation. Blood.. 2019, 134(20): 1730-1744.

[66] Luo J, Yu FX. GPCR-hippo signaling in cancer. Cells.. 2019, 8(5): 426.

[67] Sorrentino G, Ruggeri N, Specchia Vet al. . Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol.. 2014, 164357-366.

[68] Jiang L, Li J, Zhang Cet al. . YAP-mediated crosstalk between the Wnt and Hippo signaling pathways (Review). Mol Med Rep.. 2020, 22(5): 4101-4106.

[69] Zou Y, Zhao Z, Wang Jet al. . Extracellular vesicles carrying miR-6836 derived from resistant tumor cells transfer cisplatin resistance of epithelial ovarian cancer via DLG2-YAP1 signaling pathway. Int J Biol Sci.. 2023, 19(10): 3099-3114.

[70] Valero V3rdPawlik TM, Anders RA. Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. J Hepatocell Carcinoma.. 2015, 2: 69-78

[71] Zhang J, Zhou Y, Tang PMKet al. . Mechanotransduction and cytoskeleton remodeling shaping YAP1 in gastric tumorigenesis. Int J Mol Sci.. 2019, 20(7): 1576.

[72] Park HW, Kim YC, Yu Bet al. . Alternative Wnt signaling activates YAP/TAZ. Cell.. 2015, 1624780-794.

[73] Kumar V, Vashishta M, Kong Let al. . The role of Notch, hedgehog, and Wnt signaling pathways in the resistance of tumors to anticancer therapies. Front Cell Dev Biol.. 2021, 9. 650772

[74] Kim W, Khan SK, Gvozdenovic-Jeremic Jet al. . Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest.. 2017, 127(1): 137-152.

[75] Zhao L, Lei J, Gu Set al. . A yes-associated protein 1- Notch1 receptor positive feedback loop promotes breast cancer lung metastasis by attenuating the bone morphogenetic protein 4-SMAD family member 1/5 signaling. Carcinogenesis.. 2022, 43(12): 1162-1175.

[76] Zhu M, Xu M, Zhang Jet al. . The role of Hippo pathway in ovarian development. Front Physiol.. 2023, 14: 1198873.

[77] Ajongbolo AO, Langhans SA. YAP/TAZ-associated cell signaling–at the crossroads of cancer and neurodevelopmental disorders. Front Cell Dev Biol.. 2025, 131522705.

[78] Eyden B, Banerjee SS, Shenjere Pet al. . The myofibroblast and its tumours. J Clin Pathol.. 2009, 62(3): 236-249.

[79] Mao X, Xu J, Wang Wet al. . Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer.. 2021, 201131.

[80] Kanzaki R, Pietras K. Heterogeneity of cancer-associated fibroblasts: Opportunities for precision medicine. Cancer Sci.. 2020, 11182708-2717.

[81] Ganguly D, Chandra R, Karalis Jet al. . Cancer-associated fibroblasts: versatile players in the tumor microenvironment. Cancers.. 2020, 12(9): 2652.

[82] Calvo F, Ege N, Grande-Garcia Aet al. . Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol.. 2013, 156637-646.

[83] Ege N, Dowbaj AM, Ming Jet al. . Quantitative analysis reveals that actin and src-family kinases regulate nuclear YAP1 and its export. Cell Syst.. 2018, 6(6): 692-708.e13.

[84] Athavale D, Balch C, Zhang Yet al. . The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives. Cancer Lett.. 2024, 604. 217244

[85] Zhu H, Guo S, Zhang Yet al. . Proton-sensing GPCR-YAP signalling promotes cancer-associated fibroblast activation of mesenchymal stem cells. Int J Biol Sci.. 2016, 12(4): 389-396.

[86] Xiao Y, Zhou L, Andl Tet al. . YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression. Oncogene.. 2024, 43(12): 884-898.

[87] Marziano C, Genet G, Hirschi KK. Vascular endothelial cell specification in health and disease. Angiogenesis.. 2021, 24(2): 213-236.

[88] Zhang R, Yao Y, Gao Het al. . Mechanisms of angiogenesis in tumour. Front Oncol.. 2024, 14: 1359069.

[89] Dudley AC, Griffioen AW. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis.. 2023, 26(3): 313-347.

[90] Neto F, Klaus-Bergmann A, Ong YTet al. . YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development. Elife.. 2018, 7. e31037

[91] Choi HJ, Zhang H, Park Het al. . Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. Nat Commun.. 2015, 6: 6943.

[92] Sakabe M, Fan J, Odaka Yet al. . YAP/TAZ-CDC42 signaling regulates vascular tip cell migration. Proc Natl Acad Sci U S A.. 2017, 1144110918-10923.

[93] Azad T, Ghahremani M, Yang X. The role of YAP and TAZ in angiogenesis and vascular mimicry. Cells.. 2019, 85407.

[94] Kim J, Kim YH, Kim Jet al. . YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J Clin Invest.. 2017, 12793441-3461.

[95] Ong YT, Andrade J, Armbruster Met al. . A YAP/TAZ-TEAD signalling module links endothelial nutrient acquisition to angiogenic growth. Nat Metab.. 2022, 4(6): 672-682.

[96] Nakajima H, Yamamoto K, Agarwala Set al. . Flow-dependent endothelial YAP regulation contributes to vessel maintenance. Dev Cell.. 2017, 40(6): 523-536.e6.

[97] Nagasawa-Masuda A, Terai K. Yap/Taz transcriptional activity is essential for vascular regression via Ctgf expression and actin polymerization. PLoS One.. 2017, 12(4. e0174633

[98] Lai JK, Stainier DY. Pushing Yap into the nucleus with shear force. Dev Cell.. 2017, 406): 517-518.

[99] Ma B, Chen Y, Chen Let al. . Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat Cell Biol.. 2015, 17(1): 95-103.

[100] He J, Bao Q, Zhang Yet al. . Yes-associated protein promotes angiogenesis via signal transducer and activator of transcription 3 in endothelial cells. Circ Res.. 2018, 122(4): 591-605.

[101] Shibuya M. VEGFR and type-V RTK activation and signaling. Cold Spring Harb Perspect Biol.. 2013, 5(10. a009092

[102] Zhu Q, Li J, Wu Qet al. . Linc-OIP5 in the breast cancer cells regulates angiogenesis of human umbilical vein endothelial cells through YAP1/Notch/NRP1 signaling circuit at a tumor microenvironment. Biol Res.. 2020, 531): 5.

[103] Maniotis AJ, Folberg R, Hess Aet al. . Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol.. 1999, 1553739-752.

[104] Williamson SC, Metcalf RL, Trapani Fet al. . Vasculogenic mimicry in small cell lung cancer. Nat Commun.. 2016, 7: 13322.

[105] Li M, Gu Y, Zhang Zet al. . Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res POR.. 2010, 16(2): 259-266.

[106] Baeten CI, Hillen F, Pauwels Pet al. . Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum.. 2009, 52122028-2035.

[107] Sun T, Sun BC, Zhao XLet al. . Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology.. 2011, 54(5): 1690-1706.

[108] Li YS, Liu Q, Tian Jet al. . Angiogenesis process in osteosarcoma: an updated perspective of pathophysiology and therapeutics. Am J Med Sci.. 2019, 357(4): 280-288.

[109] Shirakawa K, Kobayashi H, Sobajima Jet al. . Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res.. 2003, 5(3): 136-139.

[110] Streeter EH, Harris AL. Angiogenesis in bladder cancer—prognostic marker and target for future therapy. Surg Oncol.. 2002, 11(1–2): 85-100.

[111] Li Q, Lu J, Li Jet al. . Antibody-based cancer immunotherapy by targeting regulatory T cells. Front Oncol.. 2023, 13: 1157345.

[112] Georgoudaki AM, Prokopec KE, Boura VFet al. . Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep.. 2016, 15(9): 2000-2011.

[113] de Cicco P, Ercolano G, Ianaro A. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion. Front Immunol.. 2020, 11: 1680.

[114] Yi M, Niu M, Xu Let al. . Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol.. 2021, 14110.

[115] Galli F, Aguilera JV, Palermo Bet al. . Relevance of immune cell and tumor microenvironment imaging in the New Era of immunotherapy. J Exp Clin Cancer Res.. 2020, 39189.

[116] Stampouloglou E, Cheng N, Federico Aet al. . Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biol.. 2020, 181. e3000591

[117] Hu X, Zhang Y, Yu Het al. . The role of YAP1 in survival prediction, immune modulation, and drug response: a pan-cancer perspective. Front Immunol.. 2022, 131012173.

[118] Lebid A, Chung L, Pardoll DMet al. . YAP attenuates CD8 T cell-mediated antitumor response. Front Immunol.. 2020, 11580.

[119] Yang W, Yang S, Zhang Fet al. . Influence of the Hippo-YAP signalling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann Transl Med.. 2020, 86399.

[120] Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett.. 2017, 38761-68.

[121] Ji D, Jia J, Cui Xet al. . FAP promotes metastasis and chemoresistance via regulating YAP1 and macrophages in mucinous colorectal adenocarcinoma. iScience.. 2023, 266106600.

[122] Zhao X, Wang X, You Yet al. . Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization. Exp Cell Res.. 2020, 3911. 111979

[123] Huang YJ, Yang CK, Wei PLet al. . Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways. J Hematol Oncol.. 2017, 10160.

[124] Ibáñez-Vea M, Zuazo M, Gato Met al. . Myeloid-derived suppressor cells in the tumor microenvironment: current knowledge and future perspectives. Arch Immunol Ther Exp.. 2018, 662113-123.

[125] Trac NT, Chung EJ. Peptide-based targeting of immunosuppressive cells in cancer. Bioact Mater.. 2020, 5(1): 92-101

[126] Rashid MH, Borin TF, Ara Ret al. . Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment. Oncol Rep.. 2021, 45(3): 1171-1181.

[127] Dysthe M, Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment. Tumor microenvironment. 2020, Cham, Springer International Publishing117140.

[128] Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron.. 2013, 6(2): 169-177.

[129] Wang G, Lu X, Dey Pet al. . Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov.. 2016, 6(1): 80-95.

[130] Murakami S, Shahbazian D, Surana Ret al. . Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene.. 2017, 36(9): 1232-1244.

[131] Yang R, Cai TT, Wu XJet al. . Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer. Immunology.. 2018, 155(2): 263-272.

[132] Meng G, Wei J, Wang Yet al. . miR-21 regulates immunosuppression mediated by myeloid-derived suppressor cells by impairing RUNX1-YAP interaction in lung cancer. Cancer Cell Int.. 2020, 20: 495.

[133] Kythreotou A, Siddique A, Mauri FAet al. . PD-L1. J Clin Pathol.. 2018, 71(3): 189-194.

[134] Miao J, Hsu PC, Yang YLet al. . YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget.. 2017, 870114576-114587.

[135] Li S, Ji J, Zhang Zet al. . Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1. Mol Cell Biochem.. 2020, 475(1): 79-91.

[136] Papavassiliou KA, Marinos G, Papavassiliou AG. Targeting YAP/TAZ in combination with PD-L1 immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Cells.. 2023, 12(6): 871.

[137] Wang X, Tian L, Lu Jet al. . Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle. Oncogenesis.. 2022, 11: 54.

[138] Vallabhaneni KC, Hassler MY, Abraham Aet al. . Mesenchymal stem/stromal cells under stress increase osteosarcoma migration and apoptosis resistance via extracellular vesicle mediated communication. PLoS One.. 2016, 1111. e0166027

[139] Guo J, Duan Z, Zhang Cet al. . Mouse 4T1 breast cancer cell-derived exosomes induce proinflammatory cytokine production in macrophages via miR-183. J Immunol.. 2020, 205102916-2925.

[140] Brennan K, Martin K, FitzGerald SPet al. . A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep.. 2020, 1011039.

[141] Sidhom K, Obi PO, Saleem A. A review of exosomal isolation methods: is size exclusion chromatography the best option. Int J Mol Sci.. 2020, 21186466.

[142] Thakur A, Parra DC, Motallebnejad Pet al. . Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact Mater.. 2022, 10: 281-294

[143] Burtenshaw D, Regan B, Owen Ket al. . Exosomal composition, biogenesis and profiling using point-of-care diagnostics-implications for cardiovascular disease. Front Cell Dev Biol.. 2022, 10. 853451

[144] Maia J, Caja S, Strano Moraes MCet al. . Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol.. 2018, 6: 18.

[145] Yu W, Zhang C, Wang Yet al. . YAP 5-methylcytosine modification increases its mRNA stability and promotes the transcription of exosome secretion-related genes in lung adenocarcinoma. Cancer Gene Ther.. 2023, 301149-162.

[146] Jiang J, Wang W, Zhu Let al. . Unveiling the role of hypoxic macrophage-derived exosomes in driving colorectal cancer progression. Front Immunol.. 2023, 14: 1260638.

[147] Yan Q, Liu J, Liu Yet al. . Tumor-associated macrophage-derived exosomal miR21-5p promotes tumor angiogenesis by regulating YAP1/HIF-1α axis in head and neck squamous cell carcinoma. Cell Mol Life Sci.. 2024, 811179.

[148] Wang S, Su X, Xu Met al. . Exosomes secreted by mesenchymal stromal/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway. Stem Cell Res Ther.. 2019, 101117.

[149] Yao W, Guo P, Mu Qet al. . Exosome-derived circ-PVT1 contributes to cisplatin resistance by regulating autophagy, invasion, and apoptosis via miR-30a-5p/YAP1 axis in gastric cancer cells. Cancer Biother Radiopharm.. 2021, 364347-359

[150] Wang M, Zhao X, Qiu Ret al. . Lymph node metastasis-derived gastric cancer cells educate bone marrow-derived mesenchymal stem cells via YAP signaling activation by exosomal Wnt5a. Oncogene.. 2021, 40122296-2308.

[151] Wang M, Yu W, Cao Xet al. . Exosomal CD44 transmits lymph node metastatic capacity between gastric cancer cells via YAP-CPT1A-mediated FAO reprogramming. Front Oncol.. 2022, 12. 860175

[152] Mo Y, Leung LL, Mak CSLet al. . Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Mol Cancer.. 2023, 22(1): 4.

[153] Uchihara T, Miyake K, Yonemura Aet al. . Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing β1 integrin, enhancing drug resistance. Cancer Res.. 2020, 80163222-3235.

[154] Liu-Chittenden Y, Huang B, Shim JSet al. . Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev.. 2012, 26(12): 1300-1305.

[155] Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics.. 2020, 10(8): 3622-3635.

[156] Wang Q, Lu P, Wang Tet al. . Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation. Cancer Med.. 2020, 9(11): 3816-3828.

[157] DeRan M, Yang J, Shen CHet al. . Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep.. 2014, 9(2): 495-503.

[158] Wang W, Xiao ZD, Li Xet al. . AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol.. 2015, 17(4): 490-499.

[159] Mo JS, Meng Z, Kim YCet al. . Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol.. 2015, 17(4): 500-510.

[160] Oku Y, Nishiya N, Sugiyama Set al. . Sensitisation of cancer cells to MLN8237, an aurora-a inhibitor, by YAP/TAZ inactivation. Anticancer Res.. 2018, 38(6): 3471-3476.

[161] Tang Y, Fang G, Guo Fet al. . Selective inhibition of STRN3-containing PP2A phosphatase restores Hippo tumor-suppressor activity in gastric cancer. Cancer Cell.. 2020, 38(1): 115-128.e9.

[162] Taccioli C, Sorrentino G, Zannini Aet al. . MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget.. 2015, 6(36): 38854-38865.

[163] Zhang H, Schaefer A, Wang Yet al. . Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov.. 2020, 10(2): 288-305.

[164] Wang W, Li N, Li Xet al. . Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep.. 2015, 13(3): 524-532.

[165] Troilo A, Benson EK, Esposito Det al. . Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget.. 2016, 7(20): 28765-28782.

[166] Graham K, Lienau P, Bader Bet al. . Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent antitumor activity via blockade of Rho-GTPase signaling. Cell Chem Biol.. 2024, 31(7): 1247-1263.e16.

[167] Wang C, Zhu X, Feng Wet al. . Verteporfin inhibits YAP function through upregulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res.. 2016, 6(1): 27-37

[168] Zhang W, Gao Y, Li Pet al. . VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res.. 2014, 24(3): 331-343.

[169] Jiao S, Wang H, Shi Zet al. . A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell.. 2014, 25(2): 166-180.

[170] Pobbati AV, Han X, Hung AWet al. . Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure.. 2015, 23(11): 2076-2086.

[171] Bum-Erdene K, Zhou D, Gonzalez-Gutierrez Get al. . Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD⋅Yap protein-protein interaction. Cell Chem Biol.. 2019, 26(3): 378-389.e13.

[172] Barry ER, Simov V, Valtingojer Iet al. . Recent therapeutic approaches to modulate the hippo pathway in oncology and regenerative medicine. Cells.. 2021, 10(10): 2715.

[173] Holden JK, Crawford JJ, Noland CLet al. . Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling. Cell Rep.. 2020, 3112. 107809

[174] Hagenbeek TJ, Zbieg JR, Hafner Met al. . An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat Cancer.. 2023, 46812-828.

[175] Yap TA, Kwiatkowski DJ, Desai Jet al. . Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. Cancer Res.. 2023, 83(8_Supplement): CT006.

[176] MacLeod AR. Abstract ND11: The discovery and characterization of ION-537: a next generation antisense oligonucleotide inhibitor of YAP1 in preclinical cancer models. Cancer Res.. 2021, 8113_SupplementND11.

[177] Han X, Guo J, Jin Xet al. . Abstract 7575: BPI-460372, a covalent, irreversible TEAD inhibitor in Phase I clinical development. Cancer Res.. 2024, 846_Supplement7575.

[178] Tolcher AW, Lakhani NJ, McKean Met al. . A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors. J Clin Oncol.. 2022, 4016_supplTPS3168.

[179] Chellappan S, Lawrence NJ, Mudiyanselage SRM. YAP1 inhibitors that target the interaction of YAP1 with OCT4. United States patent US10906874B2. 2021.

[180] Chen MJ, Wang YC, Wu DWet al. . Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer. Pathol Res Pract.. 2019, 2154801-806.

[181] Schelleckes K, Schmitz B, Ciarimboli Get al. . Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma. Clin Epigenetics.. 2017, 9: 109.

[182] Chen P, Sun C, Wang Het al. . YAP1 expression is associated with survival and immunosuppression in small cell lung cancer. Cell Death Dis.. 2023, 14(9): 636.

[183] Li LC, Chen XW, Fang Let al. . YAP1 as a novel negative biomarker of immune checkpoint inhibitors for EGFR-mutant non-small-cell lung cancer. Can Respir J.. 2023, 20234689004

[184] Gao Y, Gong Y, Lu Jet al. . Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy. Front Immunol.. 2024, 151377722.

[185] Fisher ML, Grun D, Adhikary Get al. . Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells. Oncotarget.. 2017, 866110257-110272.

[186] Kim MH, Kim CG, Kim SKet al. . YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol Res.. 2018, 63255-266.

[187] Gujral TS, Kirschner MW. Hippo pathway mediates resistance to cytotoxic drugs. Proc Natl Acad Sci U S A.. 2017, 114(18): E3729-E3738.

[188] Oku Y, Nishiya N, Shito Tet al. . Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio.. 2015, 5: 542-549.

[189] Mudianto T, Campbell KM, Webb Jet al. . Yap1 mediates trametinib resistance in head and neck squamous cell carcinomas. Clin Cancer Res.. 2021, 27(8): 2326-2339.

[190] Song S, Xie M, Scott AWet al. . A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol Cancer Ther.. 2018, 17(2): 443-454.

[191] Smith SA, Sessions RB, Shoemark DKet al. . Antiproliferative and antimigratory effects of a novel YAP-TEAD interaction inhibitor identified using in silico molecular docking. J Med Chem.. 2019, 62(3): 1291-1305.

[192] Zhang Z, Lin Z, Zhou Zet al. . Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP-TEAD protein-protein interaction. ACS Med Chem Lett.. 2014, 5(9): 993-998.

[193] Shen H, Xu X, Rong Het al. . Abstract 501: Discovery of BPI-460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations. Cancer Res.. 2023, 83(7_Supplement): 501.

[194] Heinrich T, Peterson C, Schneider Ret al. . Optimization of TEAD P-site binding fragment hit into in vivo active lead MSC-4106. J Med Chem.. 2022, 65139206-9229.

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology